CompletedPhase 1NCT05729282

Glycemic Effect of Diazoxide in NAFLD

Studying NON RARE IN EUROPE: Metabolic syndrome

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Columbia University
Principal Investigator
Joshua R Cook, MD, PhD
Columbia University
Intervention
Diazoxide oral suspension, 1 mg per kg per dose(drug)
Enrollment
24 enrolled
Eligibility
18-70 years · All sexes
Timeline
20232025

Study locations (1)

Collaborators

University of California, Berkeley · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05729282 on ClinicalTrials.gov

Other trials for NON RARE IN EUROPE: Metabolic syndrome

Additional recruiting or active studies for the same condition.

See all trials for NON RARE IN EUROPE: Metabolic syndrome

← Back to all trials